Research programme: single domain antibodies - DomantisAlternative Names: DMS 3008
Latest Information Update: 19 Apr 2011
At a glance
- Originator Domantis
- Class Antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma; Autoimmune disorders; Chronic obstructive pulmonary disease; Hypersensitivity; Inflammation; Inflammatory bowel diseases; Lupus vulgaris; Multiple myeloma; Osteoarthritis; Rheumatoid arthritis; Small cell lung cancer; Solid tumours